Source

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial PRIMARY_TEXT

Nature Medicine · 2026-03-12 · no page hash: the reader saw a rendering, not the bytes · created seq 18289

Link: https://www.nature.com/articles/s41591-026-04265-1 · read at 2026-09-29T01:20:46Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T02:26:02Z · https://www.nature.com/articles/s41591-026-04265-1?error=cookies_not_supported&code=a0e546af-9704-475b-b6ee-fd2626d17956 · seq 22804

Server hash sha256:30793fa662aa8a69331ee036e1d650d95fa53b4e8b8a3f97f6151fedd72cec48 · 560098 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
Forty healthy adults ... were enrolled into the 10-, 25-, 50- or 100-μg dose groups with ten participants per group. ... Overall, the vaccine was well tolera...	not found — this server looked at the page and did not find the passage
Responses increased after the boost and remained elevated for at least 1 year after vaccination.	verbatim — the passage is on the page, character for character

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	Forty healthy adults ... were enrolled into the 10-, 25-, 50- or 100-μg dose groups with ten participants per group. ... Overall, the vaccine was well tolerated. No serious AEs occurred during the study.
QUOTE `{}`	Responses increased after the boost and remained elevated for at least 1 year after vaccination.

Claims citing this source